Health Canada Licensed
MyCare Psychiatry
-
Clozapine
-
Total Risperidone / Paliperidone
-
Total Aripiprazole
-
Quetiapine
-
Olanzapine
The MyCare Psychiatry TDM assays provide quantitative insights for six of the most common antipsychotic drugs prescribed.
These assays can help improve the turnaround time of test results, provide objective information, and when used in combination with other clinical information, can lead to better-informed treatment decisions.
Clozapine
Antipsychotic Product Performance
| Assay Range ng / mL | Within-Laboratory Precision, %CV | Method Comparison to LC-MS/MS | ||||
| Low Control | Medium Control | High Control | Slope | Intercept | Correlation Coefficient | |
| 68 – 1500 | 5.4 | 4.4 | 4.5 | 1.037 | -27.8 | 0.9269 |
Expected Values
CPA Guidelines – For clozapine, at least 8 but preferably 12 weeks at a dose of 400 mg/d is an adequate trial; where available, obtaining trough levels 350 ng/mL (1100 nM/L) for once-a-day dosing and 250 ng/mL for equal divided dosing is suggested.1
Total Risperidone
Measures both Risperidone and Paliperidone
Antipsychotic Product Performance
Risperidone
| Assay Range ng / mL | Within-Laboratory Precision, %CV | Method Comparison to LC-MS/MS | ||||
| Low Control | Medium Control | High Control | Slope | Intercept | Correlation Coefficient | |
| 16 – 120 | 3.7 | 2.8 | 3.3 | 0.98 | 1 | 0.96 |
Paliperidone
| Assay Range ng / mL | Within-Laboratory Precision, %CV | Method Comparison to LC-MS/MS | ||||
| Low Control | Medium Control | High Control | Slope | Intercept | Correlation Coefficient | |
| 16 – 120 | 3.7 | 2.7 | 3.3 | 1.00 | 3 | 0.94 |
Recommended therapeutic reference ranges, laboratory alert levels and levels of recommendation for therapeutic drug monitoring*
Risperidone
| Level | Therapeutic reference range (ng/mL) | Laboratory alert level (ng/mL) |
| 2 | 20 – 60 | 120 |
Paliperidone
| Level | Therapeutic reference range (ng/mL) | Laboratory alert level (ng/mL) |
| 2 | 20 – 60 | 120 |
Total Aripiprazole
Antipsychotic Product Performance
| Assay Range ng / mL | Within-Laboratory Precision, %CV | Method Comparison to LC-MS/MS | ||||
| Low Control | Medium Control | High Control | Slope | Intercept | Correlation Coefficient | |
| 45 – 1000 | 8.3 | 4.0 | 3.9 | 1.01 | 2.56 | 0.98 |
Recommended therapeutic reference ranges, laboratory alert levels and levels of recommendation for therapeutic drug monitoring*
| Level | Therapeutic reference range (ng/mL) | Laboratory alert level (ng/mL) |
| 2 | 150 – 500 | 1000 |
Quetiapine
Antipsychotic Product Performance
| Assay Range ng / mL | Within-Laboratory Precision, %CV | Method Comparison to LC-MS/MS | ||||
| Low Control | Medium Control | High Control | Slope | Intercept | Correlation Coefficient | |
| 34 – 700 | 7.4 | 3.7 | 3.7 | 1.03 | 13.55 | 0.92 |
Recommended therapeutic reference ranges, laboratory alert levels and levels of recommendation for therapeutic drug monitoring*
| Level | Therapeutic reference range (ng/mL) | Laboratory alert level (ng/mL) |
| 2 | 20 – 60 | 120 |
Olanzapine
Antipsychotic Product Performance
| Assay Range ng / mL | Within-Laboratory Precision, %CV | Method Comparison to LC-MS/MS | ||||
| Low Control | Medium Control | High Control | Slope | Intercept | Correlation Coefficient | |
| 22 – 114 | 4.6 | 1.9 | 3.7 | 1.038 | -0.1 | 0.98 |
Recommended therapeutic reference ranges, laboratory alert levels and levels of recommendation for therapeutic drug monitoring*
| Level | Therapeutic reference range (ng/mL) | Laboratory alert level (ng/mL) |
| 1 | 20 – 80 | 100 |
